Information Transparency in the Drug Approval Process (Reply)

Responding to ODAC members who accused them of misrepresenting the advisory committee’s review of adjuvant sunitinib, the authors maintain that the committee discussion placed excessive focus on disease-free survival over overall survival, even though two randomized trials already showed no OS improvement—making the question of whether DFS is a good surrogate for OS immaterial.